REDWOOD CITY, Calif.,
March 7, 2014 /PRNewswire/ -- AcelRx
Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical
company focused on the development and commercialization of
innovative therapies for the treatment of acute and breakthrough
pain, today announced that Richard
King, President and CEO will present a Company update at the
following conference:
26th Annual Roth Conference
Date:
Tuesday, March 11, 2014
Location: The Ritz Carlton, Laguna
Niguel, CA
Presentation Time: 11:30 am ET, 8:30
am PT
This presentation will be webcast live and can be accessed
through the Investors page at www.acelrx.com. For those not
available to listen to the live broadcast, a replay of this
presentation will be archived for 90 days and available through the
Investors page on www.acelrx.com.
About AcelRx Pharmaceuticals, Inc.
AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical
company focused on the development and commercialization of
innovative therapies for the treatment of acute and breakthrough
pain. AcelRx's lead product candidate, Zalviso™, is designed to
solve the problems associated with post-operative intravenous
patient-controlled analgesia which has been shown to cause harm to
patients following surgery because of the side effects of morphine,
the invasive IV route of delivery and the complexity of infusion
pumps. AcelRx has announced positive results from each of the
three completed Phase 3 clinical trials for Zalviso, and has
submitted an NDA to the FDA seeking approval for Zalviso in the
treatment of moderate-to-severe acute pain in adult patients in the
hospital setting. AcelRx plans to initiate a Phase 3 clinical
trial for ARX-04, a product candidate for the treatment of
moderate-to-severe acute pain in a medically supervised setting,
during the second half of 2014. The company has two additional
pain treatment product candidates, ARX-02 and ARX-03, which have
completed Phase 2 clinical development. For additional
information about AcelRx's clinical programs, please visit
www.acelrx.com
Forward Looking Statements
This press release contains forward-looking statements,
including, but not limited to, statements related to submission of
the NDA for Zalviso, planned or anticipated future clinical
development of AcelRx Pharmaceuticals' product candidates,
including planned Phase 3 clinical trail for ARX-04, and the
therapeutic potential of Zalviso and other AcelRx Pharmaceuticals'
product candidates. These forward-looking statements are
based on AcelRx Pharmaceuticals' current expectations and
inherently involve significant risks and uncertainties.
AcelRx Pharmaceuticals' actual results and the timing of
events could differ materially from those anticipated in such
forward-looking statements as a result of these risks and
uncertainties, which include, without limitation, risks related to:
AcelRx's ability to receive regulatory approval for Zalviso; any
delays or inability to obtain and maintain regulatory approval of
its product candidates, including Zalviso, in the United
States and Europe; the success, cost and timing of AcelRx
Pharmaceuticals' product development activities and clinical
trials, including planned Phase 3 clinical trail for ARX-04; the
market potential for its product candidates; and other risks
detailed in the "Risk Factors" and elsewhere in AcelRx's U.S.
Securities and Exchange Commission filings and reports, including
its Quarterly Report on Form 10-Q filed with the SEC on
November 5, 2013. AcelRx undertakes
no duty or obligation to update any forward-looking statements
contained in this release as a result of new information, future
events or changes in its expectations.
Logo -
http://photos.prnewswire.com/prnh/20130226/MM67303LOGO
SOURCE AcelRx Pharmaceuticals, Inc.